HIV status may affect cervical cancer treatment success – new study investigates

NCT ID NCT07167069

Ongoing Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at 180 women in India with cervical cancer who are receiving standard chemoradiation. Half are HIV-positive and half are HIV-negative. Researchers want to see if HIV affects how often patients complete treatment and how severe side effects are. The goal is to learn whether HIV status changes treatment outcomes, which could help tailor care for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy and chemotherapy (cisplatin)
What this could lead to: If successful, this could help doctors understand how HIV affects cervical cancer treatment, leading to better care for HIV-positive patients.
What could go wrong: This is an observational study, not testing a new treatment. It may not find clear differences, and results may not apply outside India.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer HIV infectious disease HIV Seropositivity Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER HIV NEGATIVE HIV POSITIVE

Contacts and locations

Locations

Tata Memorial Hospital

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.